Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimu...See more
Headquarter United States of America |
Countries of operation United States of America, Singapore |
Funding status Publicly listed on stock exchange |
Company type MNC / Large Enterprise |
Medical Affairs Strategy and Scientific Engagement (Asia)